Technical Analysis for PRTG - Portage Biotech Inc.

Grade Last Price % Change Price Change
A 39.9 -6.80% -2.91
PRTG closed down 6.8 percent on Friday, June 18, 2021, on 2.21 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical PRTG trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -6.80%
Older End-of-Day Signals for PRTG ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Portage Biotech Inc. Description

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Immunology Solid Tumors Immune System Antibodies Interferon Biotechnology Products Acute Kidney Injury

Is PRTG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 44.9763
52 Week Low 26.05
Average Volume 17,973
200-Day Moving Average 0.00
50-Day Moving Average 29.78
20-Day Moving Average 32.09
10-Day Moving Average 35.70
Average True Range 2.37
ADX 35.43
+DI 40.54
-DI 5.23
Chandelier Exit (Long, 3 ATRs) 37.86
Chandelier Exit (Short, 3 ATRs) 33.45
Upper Bollinger Bands 42.04
Lower Bollinger Band 22.13
Percent B (%b) 0.89
BandWidth 62.03
MACD Line 3.09
MACD Signal Line 1.84
MACD Histogram 1.2483
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 49.97
Resistance 3 (R3) 50.55 47.76 48.30
Resistance 2 (R2) 47.76 45.20 47.48 47.74
Resistance 1 (R1) 43.83 43.61 42.44 43.26 47.18
Pivot Point 41.05 41.05 40.35 40.76 41.05
Support 1 (S1) 37.11 38.48 35.72 36.54 32.62
Support 2 (S2) 34.33 36.89 34.04 32.06
Support 3 (S3) 30.40 34.33 31.50
Support 4 (S4) 29.83